The author browsed the relevant news and found that many pharmaceutical companies have announced their 2017 results. For some pharmaceutical companies, 2017 is actually a rising period of enterprise development, and both the product performance and the research and development strength of the company have made great breakthroughs. However, some enterprises have been affected by unfavorable factors and entered the bottleneck period. At this time, enterprises need to take timely measures to make correct and reasonable planning. The author has compiled the performance analysis of the relevant companies in 2017, and quickly look at what these companies have achieved in the past year.
Children's medicine stimulates the rebound of sunflower pharmaceutical industry
Sunflower Pharmaceutical is a company mainly engaged in research and development and production of children's medicine. In January 2018, the operating income of sunflower medicine increased by 101.63% compared with the same period of last year. Among them, the small sunflower children's medicines accounted for nearly 50% of the company's operating income. Compared with the same period of last year, it increased by 115.40%. The author understands that in 2017, Sunflower Pharmaceuticals focused on children's medicines, and created a “golden single productâ€, and enhanced the company's industry status through large gold products.
For the results achieved in 2017, Sunflower Pharmaceuticals said that it will continue to enhance the brand value and influence of its products and actively stimulate sales. In the future, Sunflower Pharmaceuticals will further upgrade its children's medicine products to protect children's life and health, and strive to build a leading position in the field of children's medicine.
Green Leaf Pharmaceutical's strong growth and deep layout of innovative products
According to the 2017 financial report of Luye Pharmaceutical, the company's performance showed strong growth, domestic and international business went hand in hand, and the new drug research and development and listing process in the domestic and overseas markets were promoted. Specifically, Luye Pharmaceutical's sales in 2017 were 3.82 billion yuan, up 30.7% year-on-year. The normalized EBITDA was 1.49 billion yuan, up 30.6% year-on-year; the net profit attributable to shareholders was 1.06 billion yuan, an increase of 19.0%.
Luye Pharma said that in 2017, not only the existing product line will continue to show strong vitality, but also follow the policy opportunities in the research product line, speed up the registration and accelerate the R&D process. It is reported that in 2017, based on the development of core products, Luye Pharmaceutical vigorously promoted research and development projects, and the net increase in research and development expenses was about 100 million yuan, and achieved great results. In terms of overseas mergers and acquisitions, the synergy effect of Luye Pharmaceutical's domestic and international strategic business has emerged. It is expected that in 2018, Luye Pharmaceutical will reshape its global strategy and deepen its future product line.
Sansheng Pharmaceutical's 2017 revenue increased by 33.5% year-on-year
It is reported that in 2017, Sansheng Pharmaceutical's operating income was 3.734 billion yuan, up 33.5% year-on-year; EBITDA was 1.477 billion yuan, up 29.0% year-on-year; net profit attributable to parent company was about 935 million yuan. It increased by 31.3% year-on-year. In addition, the company's four core products, TBI Australia, Yisaipu, Yibbio and Saibo continue to maintain a leading position in the Chinese market.
In 2017, Sansheng Pharmaceutical also made great progress in many businesses. For example, in research and development, Sansheng Pharmaceutical obtained clinical approval for the drug. As of December 31, 2017, the company has 31 research products covering the five major fields of oncology, autoimmune diseases and other diseases, nephrology, metabolism and dermatology, 16 of which are national first-class drugs.
Shijiazhuang Group's net profit growth in 2017 exceeded 30%
Shijiazhuang Group achieved total revenue of approximately HK$15,462.5 million in 2017, representing a year-on-year increase of 25%. Net profit attributable to shareholders of listed companies was approximately HK$2.771 billion, representing a year-on-year increase of 31.9%. In 2017, Shijiazhuang Group not only achieved high performance, but also overseas ANDA number blowouts. Many new drugs also obtained FDA-issued orphan drug qualifications.
According to the financial report, the company is currently researching about 200 new products, mainly in the fields of cardiovascular and cerebrovascular diseases, diabetes and other metabolic diseases, anti-tumor, and nervous system. In addition to paying attention to the research and development of products, Shijiazhuang Group also pays attention to the secondary development of products, including new indications, new dosage forms, etc., which also brings new market space and opportunities for its products.
The top three in the pharmaceutical circulation industry, PK
In March, the top three pharmaceutical companies in the pharmaceutical industry, China Resources Medicine and Shanghai Pharmaceuticals successively announced their respective statements. According to their respective reports, the pharmaceutical distribution revenue of the three companies increased by 7.5%, 10.7% and 7.0% respectively, and only China Resources Pharmaceutical maintained a double-digit growth level. Although the sales growth of Sinopharm and Shanghai Pharmaceuticals slowed down, the financial statements of these two companies disclosed that their 2017 asset-liability ratio was only about 2%.
In addition, Sinopharm’s retail business maintained its leading position among the three giants. The total retail sales of pharmaceuticals for the year reached 12.4 billion yuan, a year-on-year increase of 21%. In the face of the pressure of the two-vote system, China Resources Medical has carried out upstream resource expansion on the one hand, and distributed logistics and intelligence integration system on the other hand to the downstream. In 2017, Shanghai Pharmaceuticals launched a merger and acquisition, which strengthened its competitiveness and actively responded to the two-vote system.
Greenhouse Plastic Plastic Clamps
Greenhouse Plastic Plastic Clamps,Greenhouse Structure Connecting Clamps,Agricultural Greenhouses Clamps,Plastic Clamps
JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.thgreenhouse.com